Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

British Columbia latest to offer Seroquel XR

This article was originally published in Scrip

Executive Summary

The British Columbia government has added AstraZeneca's schizophrenia drug Seroquel XR (quetiapine fumarate) to its PharmaCare formulary, joining Quebec and Ontario in providing the extended-release formulation as a treatment option. The addition of the drug, which offers a once-daily alternative to many other schizophrenia treatments, has been praised by Gary Blacken, executive director of the British Columbia Schizophrenia Society, who said Seroquel XR would be easy to use, accessible and could help improve both the management of the illness and patients' quality of life.

Topics

Related Companies

UsernamePublicRestriction

Register

SC005258

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel